Lehtonen et al-HDY-11-OR0193-SNP genotypes

The SNP genotypes of the pied flycatcher individuals utilised in this study by population. Data have been collected in the field and the genotypes subsequently generated in a genetics laboratory. The loci are listed at the start of the page, in the order that they presented in in the file (left to right).The alleles are in 2-digit format, one column per locus. Z-linked loci are denoted with a Z and haplotypes denoted with the abbreviaiton 'hap'. Population names correspond to the sampling site of the individual (e.g. Jeseniky = Jeseniky Mountains, the Czech Republic) as presented in Table 1 of the publication

Lehtonen et al-HDY-11-OR0193R- microsatellite genotypes Dartmoor

The microsatellite genotypes for the pied flycatchers collected from Dartmoor, which have not previously been published elsewhere. Data have been collected in the field and the genotypes subsequently generated in a genetics laboratory. The alleles are in 2-digit format, one column per locus. The loci are listed at the start of the page, in the order that they presented in in the file (left to right). The microsatellite data for the other populations is the same as that presented in Lehtonen et al. 2009 Molecular Ecology 18:4463-447

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients.

Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 symptoms randomised to receive molnupiravir (n = 253) or Usual Care (n = 324) were recruited to study viral and antibody dynamics and the effect of molnupiravir on viral whole genome sequence from 1437 viral genomes. Molnupiravir accelerates viral load decline, but virus is detectable by Day 5 in most cases. At Day 14 (9 days post-treatment), molnupiravir is associated with significantly higher viral persistence and significantly lower anti-SARS-CoV-2 spike antibody titres compared to Usual Care. Serial sequencing reveals increased mutagenesis with molnupiravir treatment. Persistence of detectable viral RNA at Day 14 in the molnupiravir group is associated with higher transition mutations following treatment cessation. Viral viability at Day 14 is similar in both groups with post-molnupiravir treated samples cultured up to 9 days post cessation of treatment. The current 5-day molnupiravir course is too short. Longer courses should be tested to reduce the risk of potentially transmissible molnupiravir-mutated variants being generated. Trial registration: ISRCTN30448031